HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

B S Dwarakanath Selected Research

Deoxyglucose (2 Deoxy D glucose)

1/2013Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas.
9/2009Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.
9/2009Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects.
9/2009Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro.
9/2009Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose.
9/2009Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma.
9/2006Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line.
4/2006Enhancement of radionuclide induced cytotoxicity by 2-deoxy-D-glucose in human tumor cell lines.
8/2005Glycolytic inhibitor, 2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro.
1/2005The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD

B S Dwarakanath Research Topics

Disease

18Neoplasms (Cancer)
01/2013 - 05/2002
14Glioma (Gliomas)
01/2013 - 05/2002
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2005 - 05/2002
4Necrosis
01/2013 - 01/2003
2Glioblastoma (Glioblastoma Multiforme)
01/2013 - 12/2002
2Ehrlich Tumor Carcinoma
01/2005 - 12/2004
1Body Weight (Weight, Body)
09/2009
1Anoxia (Hypoxia)
02/2009
1Parasitemia
08/2007
1Malaria
08/2007
1Infection
08/2007
1Ascites
01/2005
1Leukemia
07/2004
1Carcinoma (Carcinomatosis)
11/2003
1Breast Neoplasms (Breast Cancer)
12/2002

Drug/Important Bio-Agent (IBA)

11Deoxyglucose (2 Deoxy D glucose)IBA
01/2013 - 12/2004
7Glucose (Dextrose)FDA LinkGeneric
01/2013 - 08/2005
5DNA (Deoxyribonucleic Acid)IBA
08/2005 - 09/2004
4Adenosine Triphosphate (ATP)IBA
09/2009 - 08/2005
3Etoposide (VP 16)FDA LinkGeneric
01/2005 - 07/2004
2Radioisotopes (Radionuclides)IBA
04/2006 - 12/2002
2Cyclin B1IBA
07/2005 - 12/2003
26-Aminonicotinamide (6 Aminonicotinamide)IBA
12/2004 - 12/2003
2PoisonsIBA
09/2004 - 07/2004
2CamptothecinIBA
09/2004 - 07/2004
2trioctyl phosphine oxide (TOPO)IBA
09/2004 - 07/2004
2Dihydrotachysterol (AT 10)IBA
11/2003 - 05/2002
1CarbohydratesIBA
08/2010
1Nucleic AcidsIBA
08/2010
1LipidsIBA
08/2010
1Proteins (Proteins, Gene)IBA
08/2010
1Biological Markers (Surrogate Marker)IBA
08/2010
1OxygenIBA
02/2009
1Verapamil (Calan)FDA LinkGeneric
08/2007
1CalciumIBA
08/2007
1Chloroquine (Aralen)FDA LinkGeneric
08/2007
1Nifedipine (Adalat)FDA LinkGeneric
08/2007
1AntigensIBA
08/2007
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
08/2007
1Carbon MonoxideIBA
12/2006
1tebufenozide (Mimic)IBA
09/2006
1Fluorescein-5-isothiocyanate (FITC)IBA
01/2006
1Annexin A5IBA
01/2006
1CyclinsIBA
07/2005
1CytotoxinsIBA
01/2005
1Bisbenzimidazole (Hoechst 33258)IBA
12/2004
1Topoisomerase InhibitorsIBA
07/2004
1HOE 33342 (Hoechst 33342)IBA
08/2003
1LigandsIBA
08/2003
11-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2003
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2003
1Cysteine (L-Cysteine)FDA Link
12/2002
1Epidermal Growth Factor (EGF)IBA
12/2002
1Silica GelIBA
12/2002
1AntibodiesIBA
12/2002
1methyl 4-mercaptobutyrimidateIBA
12/2002
16- (4- isothiocyanatobenzyl)- diethylenetriamine pentaacetic acidIBA
12/2002
1Epidermal Growth Factor Receptor (EGF Receptor)IBA
12/2002
1PENTAIBA
12/2002
1Immunoconjugates (Immunoconjugate)IBA
12/2002
1Acetic Acid (Vinegar)FDA LinkGeneric
12/2002
1Pentetic Acid (DTPA)FDA LinkGeneric
12/2002

Therapy/Procedure

9Radiotherapy
01/2013 - 05/2002
1Drug Therapy (Chemotherapy)
09/2009
1Therapeutics
02/2009
1Photochemotherapy (Photodynamic Therapy)
01/2003